PD-L1 expression levels should be considered when identifying risk factors in NSCLC patients treated with nivolumab
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Immunotherapy | Non-Small Cell Lung Cancer